Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.

Clinical and experimental medicine - 1 May 2016

Nicoś Marcin, Krawczyk Paweł, Jarosz Bożena, Sawicki Marek, Szumiłło Justyna, Trojanowski Tomasz, Milanowski Janusz

Abstract excerpt

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib-a dual inhibitor of MEK1 and MEK2) signaling pathways showed activity in patients with mutations in KRAS that can became an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Central Nervous System Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation Rate

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 25902737
DOI: 10.1007/s10238-015-0349-2
PMCID: PMC4844634

Genes

KRAS
BRAF
EGFR
DDR2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.PMID 25902737Read ↗

Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.Semantic proximity Read ↗

Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.Semantic proximity Read ↗

[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].Semantic proximity Read ↗

Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.Semantic proximity Read ↗

New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma.Semantic proximity Read ↗

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients.Semantic proximity Read ↗

EGFR and KRAS mutations in metastatic lung adenocarcinomas.Semantic proximity Read ↗

[KRAS and epidermal growth factor receptor gene mutation in non-small cell lung cancer].Semantic proximity Read ↗

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.Semantic proximity Read ↗

Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutation status in brain metastases of non-small cell lung carcinoma.Semantic proximity Read ↗

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.